Duration of Therapy. Depending on the type of treatment approach, it may be difficult to specify exact duration of services. However, some issues are more predictable, such as parent training modules to promote communication, social skills, compliance, and flexibility. Please inquire about anticipated length of therapy, even if the answer may not be precise.
Duration of Therapy. During the period of the therapeutic relationship, it is important that we review the process regularly. The contract may last from 6 weeks to 1 year or be agreed as open-ended. I would like to have two weeks’ notice so that we can discuss and come to an appropriate ending. My contract terms may be amended from time to time. In this case, I aim to give good notice and time for discussion. Professional Information I am a fully qualified Psychotherapist. I have dual training in Contemporary Psychotherapy and in Xxxxx Xxxxxx System Psychomotor Psychotherapy (PBSP). I am registered with the UK Council for Psychotherapy (UKCP) and BACP and am a member of the Community for Contemporary Psychotherapy. I adhere to the BACP and UKCP Code of Ethics and Professional Conduct, and links to these are available on request. I carry professional liability insurance cover which includes my counselling practice. I aim to provide a service which is anti discriminatory in nature and endeavour to ensure this commitment is reflected in the counselling process. Contact Outside of Therapy My telephone number and email address are provided for cancellations or changes to our appointments. Communicating outside agreed counselling sessions to be limited to making, changing or cancelling an appointment unless by prior agreement between us. Please note that my telephone is not continuously staffed, and messages will be checked irregularly during my working days. I will respond to your messages as promptly as possible. However, in case of emergencies or if you feel suicidal, it is important to contact the emergency services or The Samaritans at 116 123. If you have concerns about emergencies, please discuss them with me. I do not initiate or accept social networking friend requests from clients to maintain the confidentiality and therapeutic nature of our counselling relationship. On social media platforms, I may maintain a public professional account separate from a more anonymous one where I share personal information, pictures, interests, and political beliefs. If we become engaged in a therapeutic relationship and are connected on social media, we will cease to be connected on the platform. However, you can still see my professional posts by following my professional account. If we are acquaintances, including social media friends, but don't know each other well, it may be possible to work together as therapist and client. We will discuss any prior interaction and its implications f...
Duration of Therapy. For short-term therapy, the patient’s PCP will evaluate the need to continue warfarin when warfarin therapy has reached the expected discontinuation date and this decision will be documented. Chronic therapy, if there have been changes in the patient’s status (fall risk, bleeding complications, adherence, etc.) the anticoagulation management pharmacist will notify the PCP or supervising provider for evaluation of risk vs. benefit of continued warfarin therapy or recommendation for other anticoagulation therapy (i.e. newer oral anticoagulation medications)
Duration of Therapy. The evidence base does not offer clear guidance as to the duration of therapy. The prescription should be reviewed at least monthly within secondary care for the first 6 months to assess efficacy. Following this, the patient should be seen by the prescriber at 6-monthly intervals. The prescription may be continued if the patient remains abstinent and feels that naltrexone continues to be helpful in maintaining this. Baseline assessment and ongoing monitoring – by Specialist If there is a history of opiate dependence: There must be clear evidence of abstinence from opioids for 7 -10 days. If there is uncertainty about abstinence, naltrexone should be started after screening for opioids by firstly obtaining a negative urine dipstick for opioids then administering a short acting opiate blockade (e.g. naloxone) to screen for the presence of opioids as follows: • Administer naloxone 400mcg IM • Observe for 30 minutes • If any evidence of opiate withdrawal (including anxiety and sweating) do not proceed. Reassess or repeat the following day If abstinence from opioids is longstanding and the prescribing doctor is confident of the patient’s informed consent, naltrexone may be commenced without a naloxone challenge. Liver Function Tests: LFTs are recommended before therapy to exclude significant liver disease. There is no existing literature which identifies an exact cut-off in terms of liver function. In most cases liver function abnormalities, whether due solely to alcohol misuse or other conditions such as chronic HCV infection, are likely to deteriorate if heavy drinking continues. Therefore in the context of non- severe liver function abnormality (i.e. using Child-Xxxx Classification system to grade liver impairment, patients must be grade A or below (scores < 5)), particularly where other treatments have failed, the decision to prescribe should be based on a discussion of the risks and benefits with the patient and informed consent obtained. NICE CG 115 recommends that patients should be reviewed at least monthly for the first 6 months and subsequently at reduced intervals if the drug is considered to be effective and continued. GP / Community Team or other Primary Care monitoring responsibilities NICE does not recommend routine blood monitoring however raised LFTs have reported at 100mg+ doses, and manufacturers’ SPCs states that liver function abnormalities have been reported in the elderly and obese patients (see xxxx://xxx.xxxxxxxxx.xxx.xx/emc/ ). Monitor...
Duration of Therapy. This is something that we will negotiate between us. We may agree to work together for an initial period of 6 – 10 weeks and then review things. Face-to-Face contact outside sessions: Should we happen to meet outside our session please be aware that I will not greet you. This is to protect your privacy and maintain confidentiality. This is especially important if you are with other people. If you acknowledge me openly, then I will respond in an appropriate, professional manner. Endings: You will normally know when you are ready to finish therapy and we can address this issue within a session. I ask that you give at least one week's notice before finishing so that we have the chance to discuss your decision, but there will be no pressure on you to continue. Unacceptable Behaviour:I will not be able to work with you if you are under the influence of alcohol or other recreational substances or verbally abusive. In this event, I would have no option but to terminate the counselling agreement. CLIENT’S CONSENT TO THERAPY SIGNED………………………………………………………………………………………….. Date……………………………………………………………………………………………….. GDPR General Data Protection Regulation 2018. Please put a tick next to YES to confirm that you fully understand and give consent that data on yourself in the form of written notes will be held securely for 7 yrs in a locked filing cabinet by Xxxxxxx Xxxxxxx, Psychosexual Relationship Therapist Accredited member COSRT ……yes ………………………………………………………………………………………
Duration of Therapy. This varies according to the client’s need. It may be from a few months to a few years. End of Therapy: The client is free to terminate at any time. There is a closing process. Risks Associated with Expressive Arts Therapy: As with any psychotherapeutic process, long buried feelings may emerge. This can sometimes make the client feel worse before they feel better. Code of Ethics: In my EXAT practice, I follow the Code of Ethics set out by the Ontario Expressive Arts Therapy Association (OEATA) of which I am a member. See attached Code of Ethics.
Duration of Therapy. Time to response is 8 to12 weeks and can be longer if the loading dose is not prescribed. Further improvement may occur for up to 6 months. Maintenance therapy is long term. Baseline assessment and ongoing monitoring – by Specialist Pre-treatment assessment: Undertake pre-treatment monitoring of FBC, liver function tests (ALT and albumin), and creatinine eGFR. Lung disease: Routine CXR are no longer undertaken but clinical assessment of coexisting pulmonary disease may result in pulmonary function tests to assess lung reserve and CT assessment being undertaken. Pre-existing lung disease is not a contraindication to DMARD use but prescription is undertaken with caution. Liver disease: In patients with deranged liver biochemistry, hepatotoxic DMARDs should be used with caution, with careful attention to trends in test results. In patients with impaired liver synthetic function (e.g. cirrhosis), DMARD therapy should be used with extreme caution. Patients with chronic viral hepatitis infection should be considered for anti-viral treatment prior to DMARD initiation. Occult viral infections: Screening for occult viral infections such as HIV and hepatitis B and C should be offered and record Varicella status. GP advised of any abnormal results. In-house checklist into patient’s notes. Blood pressure: If >140/90 on two consecutive readings, 2 weeks apart, treat hypertension before commencing the drug. Consider an ECG in patients who have a history of hypertension prior to starting leflunomide. Weight: Assess for risk of weight loss which may be attributable to leflunomide. The Rheumatology Department is responsible for the pre-assessment, and for at least 6 weeks’ initial supply of stable dose, and related monitoring of leflunomide. Check FBC, eGFR, ALT and albumin every 2 weeks until a stable dose has been achieved for 6 weeks. GP / Community Team or other Primary Care monitoring responsibilities • Once a stable dose has been achieved for 6 weeks, check FBC, eGFR, ALT and albumin every month for 3 months. • Where there is a low risk of toxicity, monitoring may then be reduced to a minimum of 3- monthly, but only after discussion with the relevant consultant, and usually not in children, or in those at high risk of toxicity with renal impairment. • Risk factors for toxicity include: a history of adverse drug events, medical comorbidities including renal and liver impairment (e.g. NAFLD) and malignancy, patients at the extremes of weight (BMI <18 or >30 kg/m2 ) and...
